INCYTE CORPORATION (INCY): what the price assumes

In the published model solve dated 2026-Q2, anchored at $124.37, INCYTE CORPORATION (INCY) is priced for +3.0% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/INCY

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 8: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.4% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Incyte is a profitable biopharma built on Jakafi, its blood-cancer drug, which alone generated about $3.09 billion in 2025, with a second franchise in the skin cream Opzelura and a growing hematology-oncology portfolio behind it.
• The defining risk is concentration meeting a clock: Jakafi loses patent protection in 2028, and the entire investment case turns on whether new products replace that revenue before generics arrive.
• Watch the launch cadence; management guides 2026 total product revenue to $4.77 to $4.94 billion and targets $3 to $4 billion of non-Jakafi revenue by 2030, the bridge across the patent cliff.

Bull Case

Valuing a profitable biopharma is its own discipline, because the standard cash-flow methods systematically misjudge it. They capitalize today's earnings, but a drug company is really a portfolio of patent-protected cash streams with known expiration dates and a pipeline of binary outcomes that the methods cannot price. Incyte is the clearest version of this puzzle: it earns a 30% operating margin and sits on about $4 billion of net cash, with essentially no debt and interest covered hundreds of times over. On the surface that is a fortress, and the relative and growth-based methods actually read the price as cheap, below where they land. The catch is that the cash flow is concentrated in one drug, and the market is pricing the question every biopharma faces, which is what happens when the patent runs out.

The bull answer is that Incyte is well underway building the replacement. The current franchises are still growing: Jakafi rose 11% in 2025 to $3.09 billion, Opzelura rose 20% in Q1 2026 to $143 million, and the hematology and oncology products jumped 116% in the quarter to $204 million on Niktimvo, Monjuvi, and Zynyz. That last number is the tell: a new portfolio is scaling fast off a small base. Management has laid out a concrete bridge, targeting four major product launches across 2026 and 2027, including an extended-release Jakafi formulation, Opzelura's European expansion, Monjuvi in first-line large B-cell lymphoma, and povorcitinib, with each franchise aimed at $1 billion-plus potential.

The balance sheet is what funds the bridge without dilution. Four billion dollars of net cash lets Incyte reinvest aggressively into launches and trials while still buying back stock, with the share count edging lower rather than higher. A biotech approaching a patent cliff with a net-cash hoard, a growing second and third franchise, and a 30% operating margin to fund the transition is in a far stronger position than the typical one-drug company staring down generics with an empty pipeline and a thin balance sheet. The bull case is that the market is anchoring on the 2028 cliff while underweighting the pipeline that management is targeting to grow non-Jakafi revenue to $3 to $4 billion by 2030.

Bear Case

The advantage being chipped away is the patent wall around Jakafi, and the calendar is fixed. Incyte's own filing describes the threat directly: a generic manufacturer has sought approval with "a paragraph IV certification purporting to challenge one or more patents covering ruxolitinib composition of matter and its use", the legal mechanism by which generics enter once exclusivity lapses in 2028. Jakafi is not one product among many; at roughly $3.09 billion it is the majority of Incyte's revenue. When a single drug that large goes generic, the revenue does not erode gently, it falls off a cliff, often losing the bulk of sales within a couple of years. The 30% operating margin and the net-cash fortress both rest on a franchise with a known expiration date, and the market knows it, which is why the multiple sits at the very top of the peer distribution while the methods say the price is supported only if the replacement revenue actually shows up.

The replacement is the bear's real doubt, because pipeline math rarely lands on schedule. Management's plan depends on four launches across 2026 and 2027 all succeeding and scaling, and the early evidence is mixed: the weaker Opzelura revenue forecast for 2026 has already raised concern about whether the second franchise grows fast enough to matter against the Jakafi hole. Each new product carries its own risks, clinical, regulatory, competitive, and commercial, and the bear case is not that any one fails but that the portfolio as a whole arrives smaller or later than the bridge requires. A company that needs $3 to $4 billion of new revenue by 2030 to offset a 2028 cliff is running a tight timeline with little room for a single launch to disappoint.

The competitive dynamic compounds it. The filing notes that demand for Incyte's products "may be reduced or eliminated if our competitors develop or acquire and commercialize generic or branded products that are safer or more effective". The new franchises Incyte is counting on do not enter empty markets; they compete against entrenched therapies and other companies' pipelines. The balance sheet means this is not a solvency bear; Incyte will not run out of money. The bear case is about the gap between a fixed loss and an uncertain replacement: the price assumes the transition succeeds, and if the pipeline underdelivers, the premium multiple compresses toward where the cliff-aware methods sit, and the net cash cushions the fall without preventing it.

Valuation

The price embeds a modest-sounding assumption that hides a sharp question. At about $98 (June 27, 2026) Incyte trades near 28 times operating income, and inverting that says the market is paying for company-wide operating growth around 9% a year for five years, a pace within what Incyte has recently delivered and one most comparable companies have sustained. For most businesses that would be unremarkable. For Incyte it is not, because the five years in question straddle the 2028 Jakafi patent cliff, so steady 9% growth implicitly assumes the new portfolio more than fills the hole the largest product leaves.

The methods we use to triangulate split in a way that captures the bet precisely. The relative peer-multiple and the growth-based methods read the price as supported, landing at or below the current level, because they credit the cash flow and the forward pipeline. The asset-based lens reads slightly rich. The signal here is not that the price is broadly above every method, as it is for many premium names, but that the price is value-supported on the methods that look forward and only mildly stretched on the backward-looking ones. The tension to reconcile is that the multiple sits at the very top of the biopharma peer distribution even as the forward methods call it cheap: the market is paying a high headline multiple on current earnings precisely because it expects the pipeline to convert today's concentrated franchise into a diversified one, so the peer comparison and the forward read are answering different questions on different bases.

Solvency is the strongest single fact and bounds the downside firmly. Incyte holds about $4 billion of net cash against almost no debt, with interest coverage in the hundreds and a share count that has edged lower. That cash is not just a safety net; it is the funding for the launches that have to work, which means the company controls its own bridge rather than depending on markets to finance it. What bounds the downside is therefore the net cash plus the value of the existing franchises even in a pessimistic pipeline scenario, not a leverage risk. The buyer at this price is underwriting a successful transition across the 2028 cliff, paid for out of a fortress balance sheet, with the existing drugs and the cash as the floor if the pipeline arrives smaller than planned.

Catalysts

The recent results show the portfolio rotating in real time. For full-year 2025, Jakafi net product revenue rose 11% to $3.09 billion on a 9% increase in paid demand. In Q1 2026, Jakafi grew 7% to $758 million, Opzelura grew 20% to $143 million on demand in both atopic dermatitis and vitiligo, and the hematology and oncology products surged 116% to $204 million driven by Niktimvo, Monjuvi/Minjuvi, and Zynyz. The newer franchises are scaling fast off a small base, which is exactly the pattern the bridge across the patent cliff needs.

The forward catalysts are dense and dated. Management guides 2026 total net product revenue to $4.77 to $4.94 billion, with Jakafi at $3.22 to $3.27 billion including the initial launch of an extended-release Jakafi formulation if approved, Opzelura at $750 to $790 million including an ex-U.S. moderate-atopic-dermatitis launch in late 2026, and hematology and oncology at $800 to $880 million. Beyond the year, management targets four major launches across 2026 and 2027, including Monjuvi in first-line large B-cell lymphoma and povorcitinib, and a goal of $3 to $4 billion in non-Jakafi revenue by 2030. Each launch milestone and each regulatory decision is a catalyst, because together they determine whether the replacement revenue arrives in time for the 2028 cliff.

Peer Cohorts (Per Segment, With Filing Citations)

Oncology and dermatology pharmaceuticals (single segment) (reported)

• EXEL (EXELIXIS, INC.)
• FY2025 10-K: …the clinical evidence required to gain approval of a therapy for a rare disease. Abbreviated FDA Approval Pathways and Generic Products The Drug Price Competition and Patent Term Restoration Act of 1984 (The Hatch-Waxman Act) established two abbreviated approval pathways for drug products in which potential…
• FY2025 10-K: …for cabozantinib, zanzalintinib, or our other product candidates. For example, the FDA's OCE has many initiatives aimed at improving oncology drug development, some of which may lead to the need for additional studies, such as dose optimization. Many of these initiatives are based on guidance issued by OCE. If the…
• JAZZ (Jazz Pharmaceuticals plc)
• FY2025 10-K: …Term Loans were refinanced into a new tranche of U.S. dollar term loans Tricare program Tricare Retail Pharmacy program Tris Pharma Tris Pharma, Inc. TSC tuberous sclerosis complex TSR total shareholder return U.K. United Kingdom U.K. Bribery Act U.K. Bribery Act of 2010 U.S. United States of America U.S. GAAP U.S.…
• FY2025 10-K: …other potential indications; and • We are also evaluating the use of our CombiPlex platform in a number of therapeutic formulations and combinations in oncology as part of our internal oncology R&D activities. 18 Table of Contents Below is a summary of our key ongoing and planned development projects related to our…
• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other…
• FY2025 10-K: …of these products; • the availability of healthcare payor coverage and adequate reimbursement for the products; • public perception regarding these products; 22 • the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and • the cost-effectiveness…
• HALO (HALOZYME THERAPEUTICS, INC.)
• FY2025 10-K: …U.S., there are several different formulations for testosterone replacement therapy including intramuscular injection, transdermal patches and gels, oral formulations and nasal gels. Potential competition in the U.S. testosterone replacement market includes transdermal solutions such as AbbVie's Androgel ® 1% and…
• FY2025 10-K: SPRO (amivantamab and hyaluronidase-lpuj) for the treatment of patients with epidermal growth factor receptor-mutated locally advanced or metastatic non-small cell lung cancer. • In December 2025, Janssen received approval from the National Medical Products Administration in China for RYBREVANT FASPRO for the…
• SUPN (SUPERNUS PHARMACEUTICALS, INC.)
• FY2025 10-K: Relationships and Related Transactions, and Director Independence 161 Item 14. Principal Accounting Fees and Services 161 PART IV Item 15. Exhibits, Financial Statement Schedules 162 Item 16. Form 10-K Summary 162 SIGNATURES 2 Table of Contents Unless the content requires otherwise, the words "Supernus," "we," "our"…
• FY2025 10-K: …trial activities through all phases of clinical development; • Our execution of any collaborative, licensing, or similar commercial arrangements, and the timing of payments we may make or receive under these arrangements; • Any delays in regulatory review and approval of product candidates in clinical development; •…
• ALKS (Alkermes plc.)
• FY2025 10-K: ILIFY ASIMTUFII; CAPLYTA; RYKINDO; UZEDY; risperidone; quetiapine; olanzapine; and ziprasidone. Other pharmaceutical companies are developing products for the treatment of bipolar I disorder that, if approved by the FDA, would compete with LYBALVI. 18 In the treatment of alcohol dependence, VIVITROL competes with…
• FY2025 10-K: …TECFIDERA (dimethyl fumarate), and PLEGRIDY (peginterferon beta-1a) from Biogen; OCREVUS (ocrelizumab) from Genentech; BETASERON (interferon beta-1b) from Bayer HealthCare Pharmaceuticals; COPAXONE (glatiramer acetate) from Teva; REBIF (interferon beta-1a) and MAVENCLAD (cladribine) from EMD Serono, Inc.; GILENYA…
• CORT (CORCEPT THERAPEUTICS INC)
• FY2025 10-K: …cellular apoptosis - the tumor-killing effect many treatments are meant to stimulate. In other cancers, cortisol activity promotes tumor growth. Cortisol also suppresses the body's immune response; activating - not suppressing - the immune system is beneficial in fighting certain cancers. Many types of solid tumors…
• FY2025 10-K: …from the European Medicines Agency ("EMA"), access to the centralized marketing authorization procedure in the European Union ("EU") and, if we obtain approval, ten years of exclusive marketing rights in the EU for the treatment of patients with hypercortisolism. Oncology There is substantial evidence that cortisol…
• AXSM (AXSOME THERAPEUTICS, INC.)
• FY2025 10-K: …other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors…
• FY2025 10-K: …and development experience provide us with competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Several of these…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.